白介素-16可作为Sézary综合征发病和病情进展的标记

niwanmao

Sézary综合征是皮肤T细胞淋巴瘤中最常见的一种，随着疾病的进展，其胞内、核内的IL-16前体会逐渐丢失，而血浆中的IL-16水平则逐渐升高，同时伴随着胞膜CD26的降低。
下面为摘要：

J Clin Immunol. 2010 Sep 28. [Epub ahead of print]

Interleukin-16 as a Marker of Sézary Syndrome Onset and Stage.

Richmond J, Tuzova M, Parks A, Adams N, Martin E, Tawa M, Morrison L, Chaney K, Kupper TS, Curiel-Lewandrowski C, Cruikshank W.

Pulmonary Center, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.

Abstract

INTRODUCTION: Sézary syndrome is one of the most common forms of cutaneous T cell lymphoma (CTCL). It is characterized by skin infiltration of malignant T cells. We examined interleukin-16, a potent T cell chemoattractant and cell-cycle regulator, as a prospective marker of disease onset and stage.

METHODS: The correlation of total intracellular interleukin-16 and surface CD26 was studied by flow cytometry. Confocal microscopy was performed to determine localization of interleukin-16 at different stages of the disease. The levels of interleukin-16 in plasma and culture supernatants were examined by enzyme-linked immunoassay. Additionally, lymphocytes from stage IB patients were cultured in the presence of interleukin-16 alone and in combination with interleukin-15, and their ability to survive and proliferate was determined by cell counts and [3H]TdR incorporation.

RESULTS: The data indicate that loss of both nuclear and intracellular pro-interleukin-16 highly correspond to disease stage, with a concomitant increase in secreted mature interleukin-16 in both culture supernatants and patients' plasma that peaks at stage IB. Loss of intracellular interleukin-16 strongly corresponded to loss of surface CD26, which has been shown to occur with more advanced stage of CTCL. Nuclear translocation of pro-interleukin-16 was not observed in late stages of Sézary syndrome, indicating this loss is not reversible.

CONCLUSIONS: We propose that it is feasible to use plasma levels of IL-16 as a potential diagnostic marker of Sézary syndrome and to use loss of intracellular IL-16 as a prognostic indicator of disease severity and stage.

PMID: 20878214 [PubMed - as supplied by publisher]

全文见：http://dx.doi.org/10.1007/s10875-010-9464-8